NCT06898944 Prognosis and Risk Factors for Acute Kidney Injury
| NCT ID | NCT06898944 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Acute Kidney Injury |
| Study Type | OBSERVATIONAL |
| Enrollment | 320,000 participants |
| Start Date | 2022-08-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 320,000 participants in total. It began in 2022-08-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of our study is to analyze the accurate diagnosis and prognosis of acute kidney injury (AKI) based on its severity and to define long-term clinical and socioeconomic outcomes. Investigators defined the AKI group among adults aged 20 years or older who visited enrolled center and underwent at least two blood tests, including serum creatinine, within an interval of 7 days or less and a control group was matched 1:1 to the AKI group based on age, sex, year of visit, and baseline kidney function, forming the study population. Investigators then collected and analyzed various clinical, laboratory, and hospitalization records including demographic data, anthropometric data, laboratory data, and medical history.
Eligibility Criteria
Inclusion Criteria: * Adults over 20 years old who visited Parcitipating Medical Center (Seoul National University Hospital, Bundang Seoul National University Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center) between 2006 and 2021 * The AKI group is defined as individuals meeting the AKI diagnostic criteria of the KDIGO Guideline (an increase in serum creatinine of ≥0.3 mg/dL or ≥1.5 times the baseline level) is enrolled. * The Control Group is defined as individuals from the study population who do not meet the AKI criteria and are matched 1:1 based on age, sex, year of visit, and baseline renal function. Exclusion Criteria: * Individuals under 20 years old * Individuals who did not undergo serum creatinine tests meeting the criteria * Individuals with pre-existing end-stage kidney disease (ESKD) who have undergone dialysis or kidney transplantation
Contact & Investigator
Dong Ki Kim, M.D. Ph.D.
PRINCIPAL INVESTIGATOR
Department of Internal Medicine, Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT06898944 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06898944 currently recruiting?
Yes, NCT06898944 is actively recruiting participants. Contact the research team at mailofsehoon@gmail.com for enrollment information.
Where is the NCT06898944 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06898944 clinical trial?
NCT06898944 is sponsored by Seoul National University Hospital. The principal investigator is Dong Ki Kim, M.D. Ph.D. at Department of Internal Medicine, Seoul National University Hospital. The trial plans to enroll 320,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.